Bedside Snapshot
- Use It For
- Empiric sepsis or septic shock with Pseudomonas or gram-negative risk; nosocomial pneumonia; intra-abdominal, skin and female pelvic infection; moderate CAP (H. influenzae, adults)
- Adult Dose
- Non-pneumonia: 3.375 g IV every 6 hr over 30 min
- Nosocomial pneumonia or sepsis protocol: 4.5 g IV every 6 hr (max 18 g/day)
- Pediatric Dose
- From 2 months: 90–112.5 mg/kg IV every 6–8 hr (per kg of piperacillin plus tazobactam); over 40 kg: adult dose. Under 2 months not established
- Onset / Duration
- Immediate on infusion; half-life 0.7–1.2 hr; dosed every 6–8 hr
- Do Not Give / Hold If
- Allergy to any penicillin, cephalosporin or beta-lactamase inhibitor; rash with blisters or mucosal lesions; fever with cytopenias (possible HLH)
- Watch For
- Anaphylaxis; acute kidney injury (especially with vancomycin); C. difficile diarrhea; neutropenia or bleeding; seizures with renal failure
- Reversal / Rescue
- No specific antidote. Anaphylaxis: epinephrine IM per protocol. Toxicity: correct renal dosing, support, hemodialysis if needed
- Must Remember
- Infuse over 30 min, never push; dose by renal function (CrCl 40 mL/min or less); in septic shock give the first dose within 1 hr of recognition
Indications
ED / ICU / Transport
- Empiric sepsis or septic shock with gram-negative or Pseudomonas risk: Broad coverage buys time while cultures come back. The Surviving Sepsis Campaign 2026 suggests covering a specific multidrug-resistant pathogen when the patient is at high risk, and suggests against it when risk is low. Add vancomycin when MRSA risk is present. Narrow the spectrum once cultures and susceptibilities return. Single-agent use in septic shock is off-label and protocol-dependent
- Nosocomial (hospital-acquired or ventilator-associated) pneumonia: FDA-labeled for moderate to severe disease. The label starts it with an aminoglycoside for presumptive treatment, and keeps the aminoglycoside only if P. aeruginosa is isolated. IDSA/ATS 2016 suggests a second gram-negative agent for selected patients only. The pairing is protocol-dependent. For Pseudomonas risk, see the pneumonia page
- Community-acquired pneumonia: The label covers only moderate-severity CAP caused by beta-lactamase-producing H. influenzae in adults (3.375 g every 6 hr). Using it for severe CAP or Pseudomonas risk is off-label and protocol-dependent
- Intra-abdominal infection: The label allows it as monotherapy, appendicitis and peritonitis included. You don't need to add metronidazole for anaerobic coverage (see the acute abdomen page)
- Skin and soft-tissue infection, and female pelvic infection: The label covers it at the non-pneumonia dose
- Febrile neutropenia: Used per institutional order set. It is off-label, not an FDA-labeled indication
Other Uses
- Pediatric intra-abdominal infection and nosocomial pneumonia: The label covers children from 2 months of age. Under 2 months is not established
Dosing & Administration
Doses vary by protocol; follow local protocols and medical direction.
Available Forms
- Single-dose vials (powder, generic): 2.25 g (2 g piperacillin / 0.25 g tazobactam), 3.375 g (3 g / 0.375 g) and 4.5 g (4 g / 0.5 g); reconstitute and dilute per the product label. Keep the dry powder at 20° to 25°C (68° to 77°F) before reconstitution. Generic vial sodium is 2.35 mEq (54 mg) per gram of piperacillin (Hospira label)
- Pharmacy bulk packages: pharmacy compounding only. Never for direct infusion (Hospira label)
- Frozen premixed Galaxy container (Baxter): 2.25 g in 50 mL, 3.375 g in 50 mL and 4.5 g in 100 mL. Store at or below -20°C (-4°F); thawed bags keep 21 days refrigerated or 24 hr at room temperature. Don't refreeze them, and don't force-thaw in a water bath or microwave. Sodium: 5.58 mEq (128 mg), 8.38 mEq (192 mg) and 11.17 mEq (256 mg) per 2.25 g, 3.375 g and 4.5 g bag. Galaxy bags come in fixed doses. Any dose other than 2.25, 3.375 or 4.5 g is not recommended. Pharmacy prepares weight-based pediatric doses from vials
Adult Dosing
| Indication | Dose & Route | Repeat / Max | Notes |
|---|---|---|---|
| Non-pneumonia serious infection (intra-abdominal, skin, female pelvic, community-acquired pneumonia) | 3.375 g IV every 6 hr, infused over 30 min (normal renal function) | Max 13.5 g/day; usual course 7 to 10 days | FDA-labeled dose; renally adjusted in Special Populations |
| Nosocomial pneumonia | 4.5 g IV every 6 hr plus an aminoglycoside, infused over 30 min | Max 18 g/day; usual course 7 to 14 days | FDA-labeled dose; give the aminoglycoside separately (see Interactions) |
| Empiric sepsis or septic shock, gram-negative or Pseudomonas coverage (protocol) | 4.5 g IV every 6 hr (usual protocol dose); first dose at the earliest time possible | Max 18 g/day | Not a labeled sepsis dose: 4.5 g is the labeled pneumonia dose; 3.375 g is the labeled non-pneumonia dose. Follow the pharmacy protocol; if the protocol uses 4.5 g, renally adjust with the nosocomial pneumonia column |
| Prolonged infusion (maintenance, protocol) | Same 24-hour total as intermittent dosing, infused over a longer period per pharmacy protocol | Max 18 g/day; no fixed duration in label | Not labeled: the US label specifies 30-min infusions only; SSC 2026 recommends prolonged infusion for maintenance doses (read from a secondary summary; full text not checked). BLING III (about 7,000 adults with sepsis, piperacillin-tazobactam or meropenem): 90-day mortality 24.9% continuous vs 26.8% intermittent, OR 0.91 (95% CI 0.81 to 1.01), not statistically significant. A 2024 meta-analysis of RCTs gave a 90-day mortality risk ratio of 0.86 (95% credible interval 0.72 to 0.98) in its Bayesian primary analysis |
Pediatric Dosing
| Indication | Dose (per kg) & Route | Max Single / Max Total | Notes |
|---|---|---|---|
| Appendicitis or peritonitis, 2 to 9 months | 90 mg/kg IV every 8 hr (80 mg piperacillin / 10 mg tazobactam per kg) | Over 40 kg: adult dose for this indication (3.375 g); no label max below 40 kg | Infuse over 30 min; dose is per kg of the combined product |
| Nosocomial pneumonia, 2 to 9 months | 90 mg/kg IV every 6 hr (80 mg piperacillin / 10 mg tazobactam per kg) | Over 40 kg: adult dose for this indication (4.5 g); no label max below 40 kg | Label-listed; pair with an aminoglycoside per the pneumonia protocol |
| Appendicitis or peritonitis, older than 9 months | 112.5 mg/kg IV every 8 hr (100 mg piperacillin / 12.5 mg tazobactam per kg) | Over 40 kg: adult dose for this indication (3.375 g); no label max below 40 kg | Same infusion time as adults |
| Nosocomial pneumonia, older than 9 months | 112.5 mg/kg IV every 6 hr (100 mg piperacillin / 12.5 mg tazobactam per kg) | Over 40 kg: adult dose for this indication (4.5 g); no label max below 40 kg | Label-listed; pair with an aminoglycoside per the pneumonia protocol |
| Children over 40 kg | Adult dose (see Adult Dosing) | Adult dose for the indication (3.375 g or 4.5 g) per dose | Label: pediatric patients over 40 kg with normal renal function receive the adult dose for the indication; at 112.5 mg/kg, a 40 kg child receives 4.5 g per dose, which is the nosocomial pneumonia dose, not the appendicitis dose |
| Under 2 months | Not established in children under 2 months | Not established | Specialist or medical-control use only |
Pediatric renal impairment: pediatric dosing with renal impairment is still undetermined, according to the label. Bring pharmacy and nephrology in.
Preparation & Administration
- Dilution: vials are reconstituted and diluted per the product label. Galaxy bags are ready to use once thawed
- Push rate: never IV push. Infuse over 30 min (label: 30 min for both adult and pediatric patients)
- Thawing (Galaxy): thaw at room temperature or in the refrigerator. Don't force-thaw in a water bath or microwave, and don't refreeze
- Line: use a dedicated line when possible. Check compatibility before sharing one (see Interactions)
- Pump: a pump is required for a timed 30-min infusion
Contraindications & Precautions
Contraindications
- Allergic reaction to any penicillin, cephalosporin or beta-lactamase inhibitor (label): the labeled contraindication is a cross-reactive beta-lactam allergy, not penicillin allergy alone
- Non-severe rash history (relative): characterize the reaction and involve pharmacy allergy assessment before dosing. A delayed rash is not proof of anaphylaxis
- None absolute in life-threatening sepsis when no labeled allergy is present
Precautions
- Critically ill patients with AKI risk: the label names piperacillin-tazobactam as an independent risk factor for renal failure in critically ill patients. Watch creatinine and urine output
- Vancomycin combination: the label warns of more acute kidney injury with vancomycin (see Interactions)
- Severe cutaneous reactions and HLH: rare, but serious. Stop and reassess at the first sign
- Bleeding and cytopenias: reversible leukopenia or neutropenia, and bleeding risk, especially with anticoagulants
- Seizures: neuromuscular excitability or seizures. The risk is higher with unadjusted doses in renal failure
- Clostridioides difficile: diarrhea can be C. difficile infection. Test for it
- Hypokalemia: the label advises watching for it in patients with low potassium reserves
- Sodium load: the Galaxy label gives 2.84 mEq sodium per gram of piperacillin (5.58, 8.38 and 11.17 mEq per 2.25, 3.375 and 4.5 g bag). The generic vial label gives 2.35 mEq per gram. It matters in heart failure or fluid restriction
Hold / Reassess If
- Rash, blisters, mucosal erosions or peeling skin: stop and reassess for severe cutaneous reaction
- Fever with new cytopenias, organomegaly or high ferritin: stop the drug and evaluate for HLH (label instructs immediate discontinuation if HLH is suspected)
- New seizures, myoclonus or encephalopathy: check renal function and dose; treat seizures per protocol
- Rising creatinine or falling urine output: reassess the dose with pharmacy, the vancomycin level and nephrotoxins
- New or worsening diarrhea: test for C. difficile before continuing
Adverse Effects & Toxicity
Common
- Diarrhea (about 11% in monotherapy trials; higher in aminoglycoside combination trials)
- Constipation, nausea and vomiting, dyspepsia
- Headache and insomnia
- Rash and itch (about 4% and 3%)
- Phlebitis at the infusion site (about 1%)
Serious / Life-Threatening
| Effect | Recognition | Management |
|---|---|---|
| Anaphylaxis | Hives, angioedema, bronchospasm, hypotension, shock | Stop infusion; epinephrine IM per protocol; airway support (see epinephrine IM page) |
| Severe cutaneous adverse reactions | Blisters, mucosal lesions, skin peeling | Stop the drug; urgent dermatology and burn-unit consult per protocol |
| Hemophagocytic lymphohistiocytosis | Persistent fever, cytopenias, organomegaly | Discontinue immediately (label); hematology consult |
| Neutropenia, bleeding | Low WBC or platelets, petechiae, bleeding, especially on anticoagulants | CBC and platelets; review need for drug; hematology input |
| Seizures or neuromuscular excitability | Myoclonus, seizure, encephalopathy, often with renal failure | Check renal function; reduce dose if renal function falls; treat seizures per protocol |
| Acute kidney injury | Rising creatinine, low urine output, especially with vancomycin | Reassess dose and nephrotoxins; nephrology for renal replacement per protocol |
| Rhabdomyolysis | Muscle pain, dark urine, rising CK | Check CK and renal function; review need for drug; treat per protocol |
| Hypokalemia | Low potassium on a routine chemistry | Replace potassium per protocol (see the potassium page) |
Overdose & Toxicity Management
- Toxicity pattern: encephalopathy, myoclonus or seizures. Usually from unadjusted doses in renal failure
- Immediate management: stop or hold the drug, support airway and circulation, check creatinine and the dose against CrCl, treat seizures per protocol
- Antidote: there is no specific antidote. Supportive care and renal dose correction are what you have
- Extracorporeal removal: hemodialysis removes the drug. The label adds 0.75 g after each dialysis session (all indications). See the hemodialysis page
Monitoring
| Parameter | When / How Often | Target / Act If |
|---|---|---|
| Clinical | Vital signs and mental status at each assessment; first hours of therapy | Hypotension or new confusion: reassess source, dose and toxicity |
| Clinical | Skin and mucosa each shift and with any new rash | Blisters, mucosal lesions or rash with fever: stop and reassess |
| Clinical | Stool pattern each shift | New or worsening diarrhea: C. difficile testing before continuing |
| Laboratory | Creatinine and urine output at least daily | Creatinine rise of 0.3 mg/dL or more within 48 hr (KDIGO AKI criteria): reassess dose and nephrotoxins; see the creatinine page |
| Laboratory | Potassium daily while on therapy | Low potassium: replace per protocol; see the potassium page |
| Laboratory | CBC with platelets at baseline and in prolonged courses | |
| Infusion safety | During each 30-min infusion | Rash, flushing, wheeze or hypotension: stop and treat anaphylaxis per protocol |
Interactions & Compatibility
Clinically Significant Interactions
| Drug / Class | Effect | What To Do |
|---|---|---|
| Vancomycin | Increased acute kidney injury (label; observational data show the strongest signal) | Follow creatinine daily; reassess need for both drugs; see the vancomycin page |
| Aminoglycosides | Piperacillin inactivates aminoglycosides in vitro; tobramycin is not compatible for simultaneous Y-site infusion. In hemodialysis patients, aminoglycoside levels (especially tobramycin) may be significantly reduced | Give separately; reconstitute and dilute separately; check compatibility |
| Heparin and oral anticoagulants | Bleeding risk; label advises coagulation monitoring | Monitor coagulation per protocol and watch for bleeding |
| Vecuronium | Prolonged neuromuscular blockade (label) | Anticipate prolonged paralysis; monitor neuromuscular block |
| Methotrexate | Reduced methotrexate clearance (label) | Avoid unless benefit outweighs risk; monitor methotrexate levels and toxicity |
| Probenecid | Increases piperacillin levels (label) | Do not co-administer unless benefit outweighs risk |
IV Compatibility
- Reconstitute and dilute per the product label. Keep aminoglycosides apart from piperacillin-tazobactam. Reconstitute, dilute and give them separately
- Label: the EDTA-containing formulation is Y-site compatible with Lactated Ringer's injection. Amikacin or gentamicin may go Y-site only under label-specified diluents and concentrations. The 3.375 g Galaxy bag is not compatible with gentamicin. Tobramycin is not compatible
- Use a dedicated line when possible. Flush between incompatible drugs per policy
- Verify with an institutional compatibility resource.
Special Populations
- Pediatrics: The label covers intra-abdominal infection and nosocomial pneumonia from 2 months of age. Use the Pediatric Dosing table. Don't dose below 2 months without specialist input. Renal dosing in children is not established.
- Neonates: safety and effectiveness are not established under 2 months of age.
- Pregnancy: piperacillin and tazobactam cross the placenta. Human data are not enough to judge drug-associated risk. Animal studies showed no fetal structural abnormalities in rats or mice. Rat studies did show fetotoxicity (reduced fetal weight, ossification changes, pup mortality), with maternal toxicity, at doses below the maximum recommended human daily dose. Use it when the infection needs treatment.
- Lactation: piperacillin passes into human milk. Tazobactam milk concentrations haven't been studied. Weigh infant exposure against the maternal infection risk.
- Older Adults: the label says patients over 65 are not at increased risk of adverse effects solely because of age. Renal function, not age, drives dose changes. AGS Beers Criteria status was not checked for this page.
- Renal Impairment: dose by CrCl (table below). If a sepsis protocol uses 4.5 g every 6 hr, renally adjust with the nosocomial pneumonia column (per pharmacy). Give the dialysis supplement after each session. The label has no CRRT regimen, so follow the pharmacy protocol (see the CRRT page).
- Hepatic Impairment: no adjustment. The label states none is warranted in cirrhosis.
- Obesity / Dosing Weight: adult doses are fixed, not weight-based. Pediatric doses are per kg, with the adult dose above 40 kg.
- Opioid-Dependent Patients: no specific adjustment established.
| CrCl (mL/min) | Non-pneumonia (3.375 g q6h normal) | Nosocomial pneumonia (4.5 g q6h normal) |
|---|---|---|
| Above 40 | 3.375 g every 6 hr | 4.5 g every 6 hr |
| 20 to 40 | 2.25 g every 6 hr | 3.375 g every 6 hr |
| Below 20 | 2.25 g every 8 hr | 2.25 g every 6 hr |
| Hemodialysis | 2.25 g every 12 hr, plus 0.75 g after each session | 2.25 g every 8 hr, plus 0.75 g after each session |
| CAPD | 2.25 g every 12 hr | 2.25 g every 8 hr |
Field & Transport Considerations
- Scope: usually hospital ED, ICU and transport RN or critical-care transport teams. EMS does not carry or start this drug. Scope varies by state and agency protocol.
- Storage & Stability: vials are dry powder at room temperature. Galaxy bags stay frozen at or below -20°C. A thawed bag keeps 21 days refrigerated or 24 hr at room temperature, and it must not be refrozen. In the vehicle, keep thawed bags away from heat and cold.
- Carried Concentration: the Galaxy 2.25 g and 3.375 g bags are 50 mL. The 4.5 g bag is 100 mL. Confirm the strength in mg on the label at handoff, because bag volume and vial strength differ.
- Infusions in Transport: a 30-min pump infusion on a dedicated or compatible line. Plan the bag or vial so the next dose is not due mid-transport without a supply. Check the line for interactions with aminoglycosides.
- Handoff Essentials: time and dose of the last dose, time the next dose is due, renal function (CrCl), culture status and any allergy history.
Clinical Pearls
Start Early in Septic Shock: get the first dose in before transfer. The Surviving Sepsis Campaign 2026 strongly recommends immediate antimicrobials, ideally within 1 hr of recognition. Don't wait for the destination unit.
Thaw the Galaxy Bag Correctly: never force-thaw it in a water bath or microwave. Never refreeze it. Discard it after the stated thawed-storage window. A bag that was warmed and then refrozen is not a safe product.
Cefepime vs Piperacillin-Tazobactam (ACORN): in ACORN, piperacillin-tazobactam did not raise the combined rate of acute kidney injury or death compared with cefepime. Cefepime patients had fewer days alive and free of delirium and coma (11.9 vs 12.2 days; OR 0.79, 95% CI 0.65 to 0.95). The authors report more neurological dysfunction with cefepime.
Vancomycin Plus Piperacillin-Tazobactam: the label and observational data tie this combination to more acute kidney injury than vancomycin with other beta-lactams. Check creatinine daily. By day 2 or 3, ask whether both drugs are still needed.
Covers Anaerobes and Pseudomonas, Not MRSA: no MRSA coverage. Pair it with vancomycin when there is MRSA risk. It does not replace source control in intra-abdominal infection.
Exam Discriminator, Allergy Scope (CCRN, CFRN, CCP-C): the labeled contraindication covers a serious allergy to any penicillin, cephalosporin or beta-lactamase inhibitor. A penicillin allergy is not the same as a cephalosporin allergy. A serious cross-class reaction, though, is a contraindication.
Pharmacology
Mechanism of Action
- Piperacillin: binds penicillin-binding proteins and blocks cell-wall cross-linking. That kills susceptible gram-negative (including Pseudomonas), gram-positive and anaerobic organisms
- Tazobactam: irreversibly inhibits many class A beta-lactamases, so piperacillin is not destroyed. It does not protect against metallo-beta-lactamases
- Clinical consequence: beta-lactam killing depends on time above the MIC. That is the reason for prolonged infusion and for early first doses
Pharmacokinetics
| Route | Onset | Peak | Duration |
|---|---|---|---|
| IV infusion (30 min) | During infusion | End of infusion | Tied to the dosing interval (every 6 to 8 hr); time above MIC drives effect |
- Half-life: 0.7 to 1.2 hr for both piperacillin and tazobactam in healthy subjects. Dose and infusion duration don't change it. Renal impairment prolongs exposure
- Metabolism: renal elimination is the main route. That is why dose changes follow CrCl
- Elimination: dialysis clears the drug. The label gives a post-dialysis supplement
Names & Classification
- Generic Name
- Piperacillin sodium and tazobactam sodium
- Brand Names
- Zosyn (US, Pfizer/Wyeth; Galaxy frozen premix by Baxter); many generic vials and pharmacy bulk packages
- Pharmacologic Class
- Penicillin with beta-lactamase inhibitor (ureidopenicillin)
- Therapeutic Class
- Antipseudomonal beta-lactam antibacterial
- Controlled Substance
- Not controlled
- ISMP High-Alert
- No
- Look-Alike / Sound-Alike
- None commonly reported; confusion risk is between the piperacillin and tazobactam dose components in pediatric mg/kg dosing
References
- Baxter Healthcare Corporation. (2026). Zosyn (piperacillin and tazobactam) injection, solution (Galaxy containers): Prescribing information. DailyMed, U.S. National Library of Medicine (revised May 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db6bd91-2106-4bfd-8cc8-38aaf1e18d17
- Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., et al. (2026). Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2026. Intensive Care Medicine, 52(5), 863–936. https://doi.org/10.1007/s00134-026-08361-1
- Dulhunty, J. M., Brett, S. J., De Waele, J. J., Rajbhandari, D., et al. (2024). Continuous vs intermittent β-lactam antibiotic infusions in critically ill patients with sepsis: The BLING III randomized clinical trial. JAMA, 332(8), 629–637. https://doi.org/10.1001/jama.2024.9779
- Abdul-Aziz, M. H., Hammond, N. E., Brett, S. J., Cotta, M. O., et al. (2024). Prolonged vs intermittent infusions of β-lactam antibiotics in adults with sepsis or septic shock: A systematic review and meta-analysis. JAMA, 332(8), 638–648. https://doi.org/10.1001/jama.2024.9803
- Qian, E. T., Casey, J. D., Wright, A., et al. (2023). Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection: The ACORN randomized clinical trial. JAMA, 330(16), 1557–1567. https://doi.org/10.1001/jama.2023.20583
- Hospira, Inc. (2024). Piperacillin and tazobactam for injection: Prescribing information (generic vial and pharmacy bulk package; label effective August 2024). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e8bbfcd-3618-43ed-a158-9d524426fdc5
- Kalil, A. C., Metersky, M. L., Klompas, M., et al. (2016). Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases, 63(5), e61. https://doi.org/10.1093/cid/ciw504
Medical Disclaimer
- For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
- Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
- Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing, paraphrasing, and formatting this information.